Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. School of Medicine / 醫學系
  4. Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence
 
  • Details

Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence

Journal
World Journal of Gastroenterology
Journal Volume
20
Journal Issue
32
Pages
11381-11393
Date Issued
2014
Author(s)
CHUN-JEN LIU  
Chang J.
PO-HUANG LEE  
Lin D.-Y.
Wu C.-C.
Jeng L.-B.
Lin Y.-J.
Mok K.-T.
Lee W.-C.
Yeh H.-Z.
MING-CHIH HO  
Yang S.-S.
Yang M.-D.
Yu M.-C.
REY-HENG HU  
Peng C.-Y.
Lai K.-L.
Chang S.S.-C.
PEI-JER CHEN  
DOI
10.3748/wjg.v20.i32.11384
URI
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84909630780&doi=10.3748%2fwjg.v20.i32.11384&partnerID=40&md5=86bd6629ff4cd27bfb0096cea38a0ae9
https://scholars.lib.ntu.edu.tw/handle/123456789/461615
Abstract
AIM: To demonstrate that administering heparanase inhibitor PI-88 at 160 mg/d is safe and promising in reducing hepatocellular carcinoma (HCC) recurrence for up to 3 year following curative resection. METHODS: A total of 143 patients (83.1% of the 172 participants in the phase II study) participated in the follow-up study. Of these patients, 50 had received no treatment, 48 had received 160 mg/d PI-88, and 45 had received 250 mg/d PI-88 during the phase II trial. Safety parameters and the following efficacy endpoints were investigated: (1) time to recurrence; (2) disease-free survival; and (3) overall survival. RESULTS: PI-88 at 160 mg/d delayed the onset and frequency of HCC recurrence, and provided a clinically significant survival advantage for up to 3 years after treatment compared with those of the control group: (1) the recurrence-free rate increased from 50% to 63%, and (2) time to recurrence at the 36th percentile was postponed by 78%. The efficacy of administering PI-88 at 250 mg/d was confounded by a high dropout rate (11 out of 54 patients). Additionally, subgroup analyses of patients with (1) multiple tumors or a single tumor ? 2 cm; and (2) hepatitis B or C revealed that administering PI-88 at 160 mg/d conferred the most significant survival advantage (56.8% improvement in disease-free survival, P = 0.045) for patients with both risk factors for recurrence. CONCLUSION: Administering PI-88 at 160 mg/d is a safe and well-tolerated dosage that may confer significant clinical benefits for patients with HCC. ? 2014 Baishideng Publishing Group Inc. All rights reserved.
SDGs

[SDGs]SDG3

Other Subjects
muparfostat; antineoplastic agent; beta glucuronidase; enzyme inhibitor; heparanase; oligosaccharide; phosphomannopentaose sulfate; adult; aged; aminotransferase blood level; Article; bleeding; cancer adjuvant therapy; cancer recurrence; controlled study; disease free survival; drug efficacy; drug safety; female; follow up; hepatitis B; hepatitis C; human; injection site pain; liver cell carcinoma; major clinical study; male; multiple cancer; multiple cycle treatment; neutropenia; overall survival; partial thromboplastin time; patient compliance; phase 2 clinical trial; randomized controlled trial; recurrence free survival; adjuvant chemotherapy; antagonists and inhibitors; Carcinoma, Hepatocellular; clinical trial; drug administration; enzymology; Liver Neoplasms; metabolism; middle aged; mortality; multicenter study; pathology; risk factor; survival; Taiwan; time; treatment outcome; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Enzyme Inhibitors; Female; Glucuronidase; Humans; Liver Neoplasms; Male; Middle Aged; Oligosaccharides; Risk Factors; Survival Analysis; Taiwan; Time Factors; Treatment Outcome
Publisher
WJG Press
Type
journal article

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science